Werewolf Therapeutics Inc (HOWL)
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies designed to activate the body’s immune response against cancer and certain immune-mediated diseases. The company uses its proprietary PREDATOR platform to create conditionally activated molecules intended to stimulate both adaptive and innate immunity while seeking to address limitations associated with conventional proinflammatory immune therapies. Its pipeline includes WTX-124, an interleukin-2-based INDUKINE candidate for advanced or metastatic solid tumors, and WTX-330, an interleukin-12-based INDUKINE candidate being developed for advanced or metastatic solid tumors and lymphoma. Additional programs in development include JZP898 for cancer, WTX-921 for inflammatory bowel disease and potentially other inflammatory conditions, as well as WTX-712 and WTX-518 for cancer. The company was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-HOWL
|
$0.96
|
-0.9% Downside
|
Fair
|
$7
|
621.6% Upside
|
Bargain
|
Fair
|
0.0%
|
November 5, 2026
|
2.9x
|
2.2x
|
47.778 M
|
25.154 M
|
0.0%
|
98.6%
|
-26.4
|
87.1%
|
